Baricitinib: First Systemic Oral Drug for Alopecia Therapy

Baricitinib, a Janus kinase inhibitor, was originally approved as anti-rheumatic drug in 2017. In 2020, it was approved for the treatment of COVID-19 in selected hospitalized adults. Baricitinib received priority review designation for treatment of adult patients with severe alopecia areata and got...

Full description

Saved in:
Bibliographic Details
Published inJournal of pharmaceutical care Vol. 10; no. 3
Main Authors Mishra, Prashant, Sinha, Sharmila, Vihan, Sandeep, Dahiya, Navdeep, Vasudevan, Biju
Format Journal Article
LanguageEnglish
Published Research Center for Rational Use of Drugs (RCRUD) 03.10.2022
Subjects
Alopecia
Baricitinib
Hair Follicle
Janus Kinase Inhibitors
Online AccessGet full text

Cover

More Information
Summary:Baricitinib, a Janus kinase inhibitor, was originally approved as anti-rheumatic drug in 2017. In 2020, it was approved for the treatment of COVID-19 in selected hospitalized adults. Baricitinib received priority review designation for treatment of adult patients with severe alopecia areata and got USFDA approval on June 23, 2022 based on the results of 02 phase III trial: BRAVE-AA1 and BRAVE-AA2. In this review, we aim to summarize the different pharmacokinetic and pharmacodynamics aspects including drug interactions, adverse effects/black box warnings and their clinical relevance. We reiterate that oral JAK inhibitors are expensive, may carry significant risks, and are not yet recommended for routine treatment of alopecia areata. There is ongoing research on other topical and oral JAK inhibitors (tofacitinib and ruxolitinib), giving hope that better treatments for alopecia areata will become available in future.
ISSN:2322-4630
2322-4509
DOI:10.18502/jpc.v10i3.10797